The 2018 ESMO Clinical Practice Guidelines on hepatocellular carcinoma (HCC) are conceived to provide the standard approach to diagnosis and local and systemic treatment of HCC.
The following Clinical Practice Guidelines will give up-to-date advice for the clinical management of patients with hepatocellular carcinoma, as well as providing an in-depth review of all the relevant data leading to the conclusions herein.
Bayer announced the submission of applications to extend the marketing authorization for its oral multi-kinase inhibitor regorafenib in the U.S.,...
This clinical study evaluates the efficacy and safety of regorafenib in patients with advanced liver cancer who have progressed on...
NICE (UK):Cabozantinib (Cabometyx) too r is recommended as an option for treating advanced hepatocellular carcinoma (HCC) in adults who have had sorafenib, only if: they have Child–Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and the company provides it according to the commercial arrangement.
The oral multikinase inhibitor regorafenib had beneficial effects in randomized clinical phase III trials compared to the placebo in patients with metastatic colorectal cancer (mCRC) who progressed on standard therapies.
Regorafenib (Stivarga®) is an oral small-molecule multiple kinase inhibitor. It is indicated worldwide for patients with metastatic colorectal cancer (mCRC).
Bayer HealthCare has announced that a Phase III trial evaluating its oncology compound Stivarga (regorafenib) tablets for the treatment of...
Bayer announced that results from the Phase III RESORCE trial show that Stivarga (regorafenib) tablets achieved a median overall survival...
This ESMO Clinical Practice Guideline provides key recommendations for managing biliary tract cancer.